Citizens JMP lowered the firm’s price target on Astria Therapeutics (ATXS) to $25 from $26 and keeps an Outperform rating on the shares. Data for navenibart expected mid-year could bolster confidence in Astria’s extended dosing intervals with the first clinical data for STAR-0310 following in Q3, the analyst tells investors in a research note. Astria is executing well on its Phase 3 ALPHA-ORBIT trial of navenibart, and Citizens continues to like navenibart’s positioning within the hereditary angioedema pipeline.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATXS:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue